Kailera Therapeutics, Inc. Common Stock (KLRA · NASDAQ)

KLRA · MARKET VIEW

Market view · as of Aug 31, 2026

Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-1.09
vs $-0.74 est · miss
52-wk position
0.0%
-37.7% vs 52w high · -4.3% 1mo

Price (last ~year)

Kailera Therapeutics (KLRA) shares reached a new 52-week low, closing at $16.21 following a 12.5% single-day decline. The clinical-stage biotechnology firm reports $0 in trailing twelve-month revenue and recorded a $121.4 million operating loss for the quarter ending June 30, 2026. While analysts maintain a $42.4 price target, the company holds $130.3 million in cash against $10.2 million in total debt.

Valuation

Market cap
$2.10B
P/B
2.149
Analyst target
$42.4

Quality & returns

Operating margin
0.0%
Profit margin
0.0%
ROE
-36.9%
ROA
-22.7%

Price movement

Last
$16.21
1-month
-4.3%
3-month
-27.6%
RSI (14)
34
vs SMA200
-20.8%
52-wk position
0.0% -37.7% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$0$-121.4M$-111.3M$-111.3M
2026-03-31$0$-84.7M$-78.9M$-84.6M
2025-03-31$0$-20.5M$-18.0M$0

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots

Aug 31Aug 3